Status: Recruiting
A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
This study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with Wilson's disease.
Participants needed: 18
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: DSciLab Co., Ltd.Updated: Jan 20, 2026Locations: 1
Eligibility criteria
Age ≥18 years old, gender not limited. [+11]
Allergy or intolerance to the investigational drug. [+17]